Xue Yangcheng, Jia Zhuoran, Liang Shichu, Dai Manyu, Liu Fang, Wu Jian, Zhao Ren
Department of Cardiology, First Affiliated Hospital of Anhui Medical University, 218 Jixi Road, Hefei, 230022, Anhui, China.
Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China.
J Cardiovasc Transl Res. 2025 Jun 4. doi: 10.1007/s12265-025-10627-w.
Early diagnosis and treatment of atrial cardiomyopathy(ACM) are crucial for patients with atrial fibrillation(AF), and further exploration of its biomarkers remains necessary. High-throughput sequencing of exosomal miRNAs was performed on blood samples from patients with persistent AF (PeAF) exhibiting mild and severe left atrial fibrosis, with supraventricular tachycardia (SVT) patients. Quantitative real-time reverse transcription polymerase chain reaction analysis validated differentially expressed miRNAs (DE miRNAs) from severe left atrial fibrosis PeAF, SVT and health controls. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses were conducted on target genes. Four exosomal DE miRNAs were identified, including miR-5106, let-7e-5p, miR-320c, and miR-382-3p. Exosomal miR-320c was down-regulated in severe left atrial fibrosis PeAF patients, while the other three miRNAs showed no significant changes. Exosomal miR-320c emerges as a potential biomarker for severe left atrial fibrosis and ACM, suggesting its suitability as a therapeutic target.
心房心肌病(ACM)的早期诊断和治疗对房颤(AF)患者至关重要,进一步探索其生物标志物仍然很有必要。对患有持续性房颤(PeAF)且伴有轻度和重度左心房纤维化的患者以及室上性心动过速(SVT)患者的血液样本进行了外泌体miRNA的高通量测序。定量实时逆转录聚合酶链反应分析验证了来自重度左心房纤维化PeAF、SVT患者和健康对照的差异表达miRNA(DE miRNA)。对靶基因进行了基因本体论和京都基因与基因组百科全书分析。鉴定出四种外泌体DE miRNA,包括miR-5106、let-7e-5p、miR-320c和miR-382-3p。外泌体miR-320c在重度左心房纤维化PeAF患者中下调,而其他三种miRNA无显著变化。外泌体miR-320c成为重度左心房纤维化和ACM的潜在生物标志物,表明其适合作为治疗靶点。